GLP-1 research expands: oral Wegovy and ‘beyond GLP-1’ targets
An oral semaglutide 25 mg became available in January 2026, and ADA 2026 featured next-generation “beyond GLP-1” approaches and new mechanism findings.
An oral semaglutide 25 mg became available in January 2026, and ADA 2026 featured next-generation “beyond GLP-1” approaches and new mechanism findings.
A unit on an insulin syringe is a volume mark, not an amount of peptide. Why mg/mL is the only valid measurement.